Physician profile
John Daniel Mccarthy
NPI 1780129429
$9,878.73
in general payments reported to CMS, 2019-2025
52 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $839 · 2021: $2,035 · 2022: $1,050 · 2023: $2,017 · 2024: $1,834 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,660 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,660.44 |
| Education | $115.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,218.30 | 2021-2025 | |
| Optinose US, INC. | $837.28 | 2020-2024 | |
| Lilly USA, LLC | $796.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $579.27 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $569.89 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $393.53 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $356.65 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $350.24 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $314.05 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Corcept Therapeutics | $271.46 | 2020-2025 | Korlym |
| Pfizer INC. | $258.85 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $255.23 | 2022 | |
| Shield Therapeutics INC | $212.76 | 2022-2025 | Accrufer |
| Novo Nordisk INC | $183.17 | 2019-2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $181.10 | 2020-2025 | Injectafer |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.